GnRH Agonist Pretreatment in Hysteroscopic Myomectomy

Azienda Ospedaliera S. Maria della Misericordia84 enrolled

Overview

The primary outcome of this study is to assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Uterine Myoma

Interventions

Triptorelin 3.75 mgDRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * submucous myoma diagnosed by vaginal ultrasonography and confirmed by diagnostic hysteroscopy * premenopausal status Exclusion Criteria: * present or past history of cancer * pregnancy * presence of associated multiple polyps * presence of \> 2 myomas * associated nonhysteroscopic surgical procedures

Locations (1)

Arbor Vitae Endoscopic Centre

Rome, Italy, Italy

Outcomes

Primary Outcomes

To assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure.

Time frame: Just finished the surgical procedure.

Secondary Outcomes

Minutes (surgical procedure time), milliliters (fluid absorption during the procedure).

Time frame: Just finished the surgical procedure.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.